Results 41 to 50 of about 299,341 (347)

Cardiometabolic Comorbidities in Patients With Psoriasis: Focusing on Risk, Biological Therapy, and Pathogenesis

Frontiers in Pharmacology, 2021
Psoriasis is a chronic inflammatory disease characterized by erythematous scaly plaques, accompanied by systemic damage that leads to the development of multiple comorbidities.
Jiangluyi Cai, Jiangluyi Cai, Lian Cui, Lian Cui, Yu Wang, Yu Wang, Ying Li, Ying Li, Xilin Zhang, Xilin Zhang, Yuling Shi, Yuling Shi   +11 more
doaj   +1 more source

Psoriasis today: experiences of healthcare and impact on quality of life in a major UK cohort [PDF]

, 2015
Aim: To establish how people with psoriasis in the United Kingdom today experience living with their condition including diagnosis, treatment, healthcare provision and impact on daily life.
Gilbert, Annie, McAteer, Helen, Nash, Avril, Penzer, Rebecca, Schofield, Julia   +4 more
core   +1 more source

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
doaj   +1 more source

Secukinumab in the treatment of psoriasis: patient selection and perspectives. [PDF]

, 2018
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Beck, Kristen M, Liao, Wilson, Yang, Eric J   +2 more
core   +1 more source

Polyethylene Glycol Ointment Alleviates Psoriasis-Like Inflammation Through Down-Regulating the Function of Th17 Cells and MDSCs

Frontiers in Medicine, 2021
Objective: To explore the possible mechanism of improving the imiquimod (IMQ)-induced psoriasis-like inflammation by using polyethylene glycol (PEG) ointment.Methods: We evaluated the appearance of psoriasis lesions by Psoriasis Area and Severity Index ...
Yan Lu, Yan Lu, Yi Xiao, Yi Xiao, Ming-Zhu Yin, Ming-Zhu Yin, Xing-Chen Zhou, Li-Sha Wu, Li-Sha Wu, Wang-Qing Chen, Yan Luo, Yan Luo, Ye-Hong Kuang, Ye-Hong Kuang, Wu Zhu, Wu Zhu   +15 more
doaj   +1 more source

Thrombospondin-1/CD47 interaction regulates Th17 and treg differentiation in psoriasis [PDF]

, 2019
Accumulating evidence on the role of Thrombospondin-1 (TSP-1) in the immune response has emerged during the last years. In spite of the importance of TSP-1 not only as anti-angiogenic factor but also as an immunomodulatory molecule, studies on the ...
Calzada, María J., Chicharro, Pablo, Cibrian, Danay, Daudén, Esteban, Fuente, Hortensia de la, Jiménez Fernández, María, Llamas Velasco, Mar, Rodriguez Jiménez, Pedro, Sevilla Montero, Javier, Sánchez-Madrid, Francisco, Trigo Torres, Laura, Vara, Alicia   +11 more
core   +2 more sources

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, EarlyView.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study [PDF]

, 2018
Background: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. Objective: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics.
Armesto, Burmester, Carrera, Davison, Edson-Heredia, Elm, Gisondi, Gisondi, Gisondi, Gordon, Gossec, Gossec, Gottlieb, Griffiths, Gupta, Honda, Kurd, Lernia, Lernia, López-Ferrer, Lümig, Menter, Menter, Menter, Mrowietz, Nestle, Ortonne, Papoutsaki, Papp, Papp, Papp, Papp, Salvarani, Sbidian, Simone, Strober, Talamonti, Talamonti, Talamonti, Vandenbroucke, Vollenhoven   +40 more
core   +1 more source

Diverse Treatment Goals in Psoriatic Arthritis: Insights From Participants in the PARC Cohort

Arthritis Care &Research, EarlyView.
Objective The aim of this study was to examine patient‐reported treatment goals among individuals with psoriatic arthritis. Methods Participants in the Psoriatic Arthritis Research Consortium completed standardized assessments, including patient‐reported outcome (PROs) instruments, between 2017 and 2020.
Astia Allenzara, Kathleen Bush, M. Elaine Husni, Soumya M. Reddy, Jose U. Scher, Ethan Craig, Joelle Koplin, Jessica A. Walsh, Alexis Ogdie   +8 more
wiley   +1 more source

2D Visualization of the Psoriasis Transcriptome Fails to Support the Existence of Dual-Secreting IL-17A/IL-22 Th17 T Cells. [PDF]

, 2019
The present paradigm of psoriasis pathogenesis revolves around the IL-23/IL-17A axis. Dual-secreting Th17 T cells presumably are the predominant sources of the psoriasis phenotype-driving cytokines, IL-17A and IL-22.
Adamopoulos, Iannis E, Alexanian, Claire, Gudjonsson, Johann, Hwang, Samuel T, Le, Stephanie T, Luxardi, Guillaume, Marusina, Alina I, Maverakis, Emanual, Merleev, Alexander A, Raychaudhuri, Siba P, Shimoda, Michiko, Tsoi, Lam C, Wang, Jenny Z   +12 more
core